Furthermore, the multivariate analyses identified BRF2 protein overexpression (P = 0.025), clinical stage (P = 0.017), E-cadherin protein overexpression (P = 0.020), and the differentiation of cancer (P = 0.046) as independent prognostic factors for progression-free survival. This evidence concerns the gene BRF2 and cancer.